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Abstract
Background: Statins improve the endothelial function in patients with coronary artery disease
(CAD). However, they contribute to the substantial decrease in coronary heart disease by reducing
plasma cholesterol levels. They also, reduce oxidative stress, stabilize the atherosclerotic plaque
and inhibit inflammatory response. These functions of statins have been briefly described as
pleiotropic effects. The aim of our study was to evaluate the effect of atorvastatin therapy on
endothelial functions in patients with CAD.
Methods: Fourty-nine patients (40 men, 9 women, mean age 59 +/- 11 years) with diagnosed CAD
were selected as the study group. The patients were given 10 mg/day atorvastatin for 12 weeks. If
the target cholesterol levels has not been achieved 6 weeks after the treatment, then the daily
atorvastatin dosage has been increased. The endothelial function was evaluated by flow mediated
dilatation (FMD) of the brachial artery.
Results: It has been figured out that 12 weeks later, atorvastatin caused a statistically significant
decrease in the plasma levels of LDL-cholesterol and total cholesterol (p < 0,0001). Meanwhile, it
was determined that the FMD got statistically significant improved 12 weeks after the atorvastatin
therapy (8,1%–4,2%, p < 0,001). However there was no statistically significant change in non-
endothelium dependent dilatation (NID).
Conclusion: Endothelium derived vasodilatation (EBD), which was non-invasively detected via
brachial artery ultrasonography, had statistically significant improvment within 12 weeks of
atorvastatin therapy whereas non-endothelium dependent dilatation (NID) had no change.
Introduction
The endothelium plays a vital role on the process of
atherosclerosis; and it functions as a barrier between the
blood and wall of the vessel [1,2]. Hypercholesterolemia
is highly associated with impaired endothelial function.
Endothelial dysfunction (ED) has a predictive value about
the future cardiovascular events [3]. ED is reversible dur-
ing the early stages of atherosclerosis. Some of the sys-
temic markers of inflammation such as C-reactive protein
(CRP) may also have predictive value for the future cardi-
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ovascular events in healty subjects, in elder patients and in
individuals with high risk. The serum level of CRP is
directly correlated with the presence and severity of coro-
nary, cerebral and peripheral arterial atherosclerosis [4].
Beyond their lipid lowering effects, statins may improve
endothelial function, reduce CRP and the risk of cardio-
vascular events. The endothelial function can be non-
invasively evaluated by FMD of the brachial artery. The
aim of our study was to evaluate the effects of atorvastatin
therapy on serum lipid levels and to evaluate the effect of
atorvastatin on endothelial function assessed by FMD of
brachial artery in patients with diagnosed CAD.
Materials and methods
Study population
Fourty-nine patients (40 men, 9 women, mean age 59 +/-
11 years) with diagnosed CAD were selected as the study
group. The inclusion cirteria for the study were described
as; having coronary artery lesions on coronary angiogra-
phy or previous myocardial infarction onset of which was
older then 6 months, having a LDL-cholesterol level
higher then 130 mg/dl and triglyceride level lower then
300 mg/dl and for diabetic population having a fasting
glucose level lower then 180 mg/dl and HbA1c level
below 8%. Our exclusion criteriae were; having a lipid
lowering drug therapy for the last two months, undergo-
ing any surgical operation within last 6 months, having an
anticoagulant therapy, renal or hepatic failure, uncon-
trolled systemic hypertension (systolic>160 mmHg,
diastolic > 100 mmHg), having a myocardial infarction,
unstable angina, stroke, angioplasty and/or coronary
artery bypass surgery within the period of last 6 months.
Ten of 59 patients were excluded from the study due to the
discordance in the treatment.
Study design
All of the patients were evaluated at the begining of the
study and at the 6th and 12th week of the study. Any
patient who had not been taking aspirin therapy was
given 300 mg aspirin daily and study was started two
weeks later.
1) Initial evaluation
At the beginning of the study a detailed medical history
was obtained, demographic data including the heights
and weights of the patients was collected and a detailed
physical examination was performed. For analysing the
fasting glucose level, lipid profile, liver functional tests,
fibrinogen and CRP, blood samples were taken. For the
assesment of the endothelial function before the treat-
ment, brachial arterial ultrasonography which is a non-
invasive test was performed. Later on all of the patients
were given NCEP step 2 diet. Special attention was paid
on not to change any other drug therapy that the patient
has already been receiving. Atorvastatin dosage was
ordered as 10 mg per day for patients whose initial LDL
cholesterol levels were below 180 mg/dl and 20 mg per
day for patients whose initial LDL levels were above 180
mg/dl.
2) 6th week evaluation
The patients whose hepatic functional tests were two
times higher then their initial levels were excluded from
the study. The aim of the therapy was to achieve either a
30% decrease in the level of LDL cholesterol or a level
under 125 mg/dl. When the expected level of LDL choles-
terol was not reached then the atorvastatin dosage was
increased to 20 mg per day for patients receiving 10 mg
per day and to 30 mg per day for patients receiving 20 mg
per day.
3) 12th week evaluation
Blood samples were taken for the re-measurement of fast-
ing glucose level, lipid profile, liver functional tests,
fibrinogen and CRP and brachial arterial ultrasonography
was repeated.
The vasomotor function of brachial artery can be evalu-
ated by brachial arterial ultrasonography and this method
is well correlated with coronary artery vasomotor function
[5]. So, we preferred to perform brachial arterial ultra-
sonography for assessing the endothelial function. The
protocol for the flow mediated dlation is performed
according to guidelines, by Corretti. M.C. et al. [6] The
medications such as nitrates, calcium antagonists, angi-
otensin converting enzyme inhibitors and beta blockers
have been discontinued one day before the examination.
The patients were wanted to lay down in supine position.
Two-dimensional images of 10–20 mm slices of the right
brachial artery were obtained via 8,5 MHz linear trans-
ducer. Later on, the largest diameter of the artery was
measured during systole via M-mode imaging. The meas-
urements were repeated three times and the arithmetic
medians were calculated. After the measurement, 250
mmHg pressure was applied to the same upper extremity
with a cuff for 5 minutes. After loosening the cuff, the
ultrasonographic views were recorded for 3 minutes and
the largest diameter of the vessel in systole was measured
(Endothelium dependent vasodilatation-EDV) (Reactive
hyperemia). After the diameter of the vessels returned to
their resting state (10 minutes later), the patient was given
2,5 mg sublingual nitroglyicerin spray and then the
images were recorded for 5 minutes and the largest diam-
eter of the vessel during systole was reached (Vasodilata-
tion independent from endothelium-NID).
Rates of EDV and NID were obtained in percentage
according to the ratio between the arterial diameters
measured at rest and arterial diameters measured afterCardiovascular Ultrasound 2007, 5:51 http://www.cardiovascularultrasound.com/content/5/1/51
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reactive hyperemia and application of nitroglyicerin. The
calculation was made according to the formula below.
% change = (D2-D1)/D1 × 100%
D1 was the initial diameter while D2 was the diameter
measured after atorvastatin therapy.
Plasma lipid and C-Reactive Protein levels
Lipid profiles and hepatic functional tests of the patients
were analyzed at the beginning, at the sixth week and at
third month of the therapy. The total cholesterol levels
were measured by Technicon Opera autoanalyser by using
trading kit (biotrol) after it dissolved. CRP was checked by
using high sensitive Dade Behring kit on Dade Behring
Nephhelometer 100 device. Dilution was applied to high
levels. CRP levels under 0,34 mg/L were accepted as nor-
mal while the levels higher were accepted as pathological.
Statistical analysis
In our study, quantitive factors were indicated as aritmetic
means +/- standard deviation and qualitative factors were
indicated as percentage. Matched t test was used for the
comparison of the brachial arterial diameters. The total
cholesterol level was evaluated via Pearson correlation
analysis according to the % change between LDL and
EBD. The correlation was considered as statistically signif-
icant for whom the coefficient of correlation was higher
then 0,05. The SPSS 11,0 package statistics program was
used for statistical work.
Results
The demographical characteristics, coronary angiographic
findings and the medications have been summarised in
Table 1. Initially, 10 mg atorvastatin was given to 41
patients (83,6%) and 20 mg to 8 patients (16,3%) and the
dosages were increased substantially according to the con-
trol levels at the sixth week of the therapy. No significant
increase was seen in the liver functional tests in any con-
trol evaluation.
Effects of atorvastatin on serum lipid and CRP levels
It has been seen that the total cholesterol and LDL choles-
terol levels got significantly decreased at the third month
of the atorvastatin therapy. The total decrease was 32,4%
for total cholesterol level and was 42,3% for LDL choles-
terol level. The triglyceride levels and HDL cholesterol lev-
els were not changed significantly. With atorvastatin
treatment, the rate of decreament in fibrinogen levels was
8,2 % (p < 0,05) while it was 31,6 % (p < 0,001) in CRP
levels.
The results of brachial arterial ultrasonography
The brachial artery diameter was 3,81 +/- 0,43 mm at rest-
ing state before treatment. At the third month of the ator-
vastatin therapy, the new resting diameter was 3,82 +/-
0,43 mm and the change had no statistically significant
meaning (p > 0,05). The dilatation formed in brachial
artery during hyperemia caused by cuff pressure (EDV)
was measured as 4,25 +/- 1,7 % at the beginning of the
therapy and 8,16 +/- 1,84 after 3 months of atorvastatin
therapy. The EDV values were increased significantly after
three months of the therapy (p < 0,0001). When com-
pared with the beginning of the therapy, it has been seen
that after application of 2,5 mg sublingual nitroglycerin
the vasodilatation independent from endothelium (NID)
did not get changed significantly after 3 months (8,74 +/-
2,58% vs 8,73 +/- 2,34, p > 0,05).
Discussion
In recent years the trials mainly have focused on non-inva-
sive detection of endothelial dysfunction which has been
accepted as an early sign of atherosclerosis. This non-inva-
sive method is based on determination of EDV and NID
via high resolution ultrasonography of brachial artery
[7,8].
There are several agents which affect endothelial func-
tions. Among these agents, Angiotensin Converting
Enzyme (ACE) inhibitors are the most widely known
agents bearing such an endothelial activity [9,10].
It has been figured out that hypercholesterolemia causes
no impairment on endothelial functions in premenopau-
sal women. This has been considered to be due to the pos-
itive effects of estrogen on endothelial functions. It has
been reported that the endothelial functions could be
improved by the use of aspirin in athersclerotic patients
and this has been considered to be associated with the
Table 1: The demographical and angiographic characteristics of 
patients
Age (year) 59. 33 ± 11. 20
Sex
(men, n=) 40 (% 81. 6)
(women, n=) 9 (% 18. 4)
BMI(kg/m2) 27. 50 ± 3. 41
Hypertension 23 (%. 47)
Diabetes 12 (% 24. 5)
Smoking 18 (% 36. 7)
Family history 13 (% 26. 5)
The diameter of Brachial artery
(men) 3.87 ± 0.41
(women) 3.56 ± 0.41





Previous revascularization (CABG or PCI) 33/49
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inhibition of constructor substance formation by aspirin
via the cyclooxygenase pathway [11].
Hypercholesterolemia is the most important risk factor in
the development of coronary atherosclerosis [12]. The
deterioration of endothelium dependent on vasodilata-
tion has been found to be related with hypercholestero-
lemia [12-15].
The oxidized LDL, which gets increased in hypercholeste-
rolemia and atherosclerosis cause impairment of
endothelial vasodilatation by decreasing NO synthase
activity [16]. The deterioration of EBD takes place before
the formation of atherosclerotic lesions [12-14]. Hyperc-
holesterolemia causes deteriation of EBD and then myo-
cardial perfusion decreases [12-17]. Statins enhance the
endothelial vasodilator and fibrinoliytic capacity by low-
ering the oxidized LDL.
The use of statins in patients with CAD and hyperlipi-
demia results in improvement of both endothelial func-
tions of coronary arteries and myocardial perfusion [18-
21]. The main causative substrate for this improvement is
endothelium derived relaxing factor (EDRF = NO).
Within 24 weeks of fluvastatin therapy, an increase in the
forearm blood flow through plethysmography has been
detected in hyperlipidemic patients with an inverse ratio
of LDL levels [22]. The same benefical effect has been also
reported with 4 weeks of simvastatin therapy [23]. In
RECIFE study, improvement in endothelial functions with
pravastatin use (40 mg/d) has been shown in such a short
time as 6 weeks [24].
In a study, Anderson et al. randomized 49 patients into
three groups with average serum cholesterol levels of 209
+/- 33 mg/dl [25]. At the end of the first year, a significant
improvement in the coronary artery dilatation by Ach has
been observed. Consequently, the authors indicated that
an improvement in endothelial functions could be
obtained in patients with CAD and unfavorable cardiac
events could be reduced with the combination of choles-
terol lowering therapy with antioxidant therapy.
In our study we hold a group that contained patients with
high risk (diagnosed CAD, 30% incidence of diabetes
mellitus) and we examined the effect of atorvastatin on
endothelial functions, by evaluating the EDV and NID on
brachial artery before and after 12 weeks of atorvastatin
therapy. At the end of 12 weeks, LDL cholesterol levels
showed a decrease of 42,3 % and endothelium dependent
vasodilatation showed a 92% increase. We found no sig-
nificant change in NID with atorvastatin therapy. Our
results were similar to the other statin studies (RECIFE
etc.) [24]. However. the method we used is a very simple
method highlighting the general status of the circulatory
system. Because it depends on ultrasonography, the exam-
ination requires experience.
As a result, in the adults who have normal vascular func-
tion, a marked improvement in endothelial functions
with 80 mg/day atorvastatin therapy was observed within
24 hours and this improvement came out before choles-
terol lowering activity. However, it has been seen that vas-
cular functions deteriorated acutely irrespective of
cholesterol levels after cessation of atorvastatin therapy
[26].
Conclusion
Statins have cholesterol lowering effects and recover
endothelial dysfunction which contributes to atheroscle-
rosis in patients with hypercholesterolemic ischemic car-
diac disease. The improvement in endothelial functions
may play a significant role in reducing the risk of future
coronary events. It is important to use statins for a long
time, because of rapid deterioration of endothelial func-
tions occurs shortly after cessation of statin therapy.
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